Right On-Target: Developing Safe and Selective Multispecific T-Cell Engagers

Technology Networks·Apr 23

This story is reported by Technology Networks. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Lab Genius' Sinclair: 'Downstream Fixes Can't Rescue a Molecule' — Why Cancer Drug Safety Must Be Designed, Not Dosed Around

finance.biggo.com·2d ago

2

T cell engagers emerge as a compelling therapeutic modality

Rockefeller University Press·Dec 26

3

Engineering the next generation of T-cell engagers

Drug Target Review·Feb 17

4

Voro Therapeutics and Alloy Therapeutics Enter Strategic Research Collaboration to Advance Next-Generation Masked T-Cell Engager Therapeutics

Business Wire·Jun 18

5

Excalipoint Launches with $68.7 Million to Advance T-Cell Engager Platforms

BioPharm International·Mar 18

6

Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives

Frontiers·Oct 14

7

InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro’s Proximity-Guided Platform

BioSpace·Jan 8

8

Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M

Fierce Biotech·Jan 7